Author:
Kastrukoff L.F.,McLean D.R.,McPherson T.A.
Abstract
SUMMARY:Multiple sclerosis patients treated with antithymocyte globulin (ATG) were re-evaluated after five years. No long term benefit was found. Notably, the group of patients with an elevated gamma globulin to total protein ration in their C.S.F. and who did particularly well after treatment with ATG also failed to show any long term benefit. Few long term detrimental effects of ATG immunosuppression were identified. The implications of the results are discussed as they relate to the use of immunosuppression in multiple sclerosis.
Publisher
Cambridge University Press (CUP)
Subject
Clinical Neurology,Neurology,General Medicine
Reference17 articles.
1. Antithymocyte antisera therapy in non-surgical immunological disease;Pirofski;Transplant Proc,1971
2. Evaluation of antithymocyte globulin in acute relapses of multiple sclerosis
3. Problems of experimental trials of therapy in multiple sclerosis: Report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis;Schumacher;Ann. N.Y. Acad. Sci,1965
4. Wirkung eines heterologen Antilymphocytenserums auf die experimentelle allergische Encephalomyelitis
5. Intensive immunosuppression in multiple sclerosis;Lance;Neurology (Minneap.),1975
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献